Last 12 months have seen almost constant down-slide - with just a bit of a dawn of hope in Feb 2025 - from $23+ down to a low of around $4.40 - $4.60, as of April 21st
The NASDAQ listing in Dec 2024 didn't do anything to interrupt that pattern.
And now we get three hot days on the ASX, ( 4 on...
Perhaps we remember too starkly the ones that got away, and reflect too little on the ones that thank goodness we didn't buy into.
Anteris re-badged - same ASX code "AVR" but the chart starts anew in December 2024, with the NASDAQ launch - initially at $6USD so $8-80-ish AUD.
After an...
After some recent missteps of mine on other stocks on my watchlist, I hesitated to get excited over this one, noting a recent good news announcement: Production option exercised for further $3.5m.
Seemed promising but I sat on my hands ...
now look at it.
Market cap was only $15.5m - before...
What happens when the company management decides :stuff it with the ASX, let's go to 'Murica:
Plan to Pursue Re-domiciliation, Nasdaq listing and US IPO
An accelerating sell-off.
One would expect a collapse like this for a biotech on bad results, but no: this is entirely from either a...
So much for the theory that $23 April Cap-Raise foreshadowed favourable developments: the sophisticated and institutional investors who bought in at that price are probably feeling rather less sophisticated now:
( I was never sophisticated, so my status unchanged )
AVR shares have been sold...
I really need to proof-read my posts: Osteopore's right issues was NOT for $0.29c per new share, it was 1/10 of that:
$0.029 cents per new share - at a 10 for 1 rights for shares held back at the record date.
Which explains the sharp drop in today's SP, from $0.31 down to close today at $0.125...
Further to my comment above that Ostepore is low-cap, $5 miil ...
... without having acquainted myself with the recent fact that OSX recently announced a right issue of 10 to 1, such that existing holders as of the record date last month, could acquire ten new shares for each share held, at an...
In case you thought March 2024 was an aberration, OSX has done it all over again for April:
They announced first in-human clinical trials commencement, 23rd April. 1st patient of 12 treated. This announcement was NOT flagged as price-sensitive ... hmmmm, how curious.
Wild spasms of share price...
DroneShield gone a Cap-raising, with a $75Mil+ issue at $0.80c
Hasn't come out of Trading Halt yet despite having announced the details yesterday (April 18th).
Perhaps there's an alteration to terms? Perhaps an expanded offer to holders for a Share-Purchase plan (thus far, $5mil for the SPP...
To re-quote myself from March 2022:
Today Anteris announced a cap-raise of 1,000,000 share issue to sophisticats and existing major holders (ASX website link, or from where-ever you get your announcements)
It's a recurrent thing. Raising $23 mil won't last long, so unless there's some...
Good afternoon Joe et al:
Being both Easter Monday, and April Fool's day, I hope entries are still open to nominate
AVR - Anteris
I'm a serial tipster of this stock, so like a broken clock is right twice a day, maybe this time? :)
🕰️
In the last month or so, Anteris has quietly gained some weight: from a bit above $17 to last close of $23.48.
Clinical results continue to trickle in, and continue to be encouraging, the most recent being March 12:
DurAVR™ First-In-Human Study and US Early Feasibility Study (update)
Cash on...
My unerring ability to pick the low has deserted me: a week or so ago I sold most, and after that it went lower!
Anteris has been belted last few days.
Closed at $16.40, which is a small improvement on intra-day low of $15.58, but still equal lowest end-of-day close for the past 18 months...
Anteris on a lumbering drift downwards, no big hurry. Last 3 months:
Today released an investor update . Lots of happy guff, but nothing strikingly new, except perhaps few more patients treated here and there.
Enough it seems to give the SP a little pick up, closing at $18.75.
In accordance...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.